OPCH Stock Recent News
OPCH LATEST HEADLINES
GILD, OPCH and AVAH demonstrate resilience with impressive earnings surprise history.
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
Option Care (OPCH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Option Care (OPCH) and Chemed (CHE). But which of these two stocks is more attractive to value investors?
OPCH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2025.
Option Care (OPCH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
OPCH, LMAT, C, FFIN and IBCP have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2025.
After reaching an important support level, Option Care Health, Inc. (OPCH) could be a good stock pick from a technical perspective. OPCH recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Call Start: 8:30 January 1, 0000 9:19 AM ET Option Care Health, Inc. (NASDAQ:OPCH ) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Nicole Maggio – Senior Vice President and Corporate Controller John Rademacher – President and Chief Executive Officer Mike Shapiro – Chief Financial Officer Conference Call Participants Matt Larew – William Blair Brian Tanquilut – Jefferies Lisa Gill – JPMorgan Pito Chickering – Deutsche Bank Constantine Davides – Citizens Joanna Gajuk – Bank of America Sarah Conrad – Goldman Sachs Operator Good day and thank you for standing by. Welcome to the Option Care Health Fourth Quarter 2024 Earnings Conference Call.
Option Care (OPCH) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.32 per share a year ago.